Market Introduction
SAM region for the estimating the market for the plasma fractionation consist of countries such as Brazil, Argentina, and rest of SAM. The region is expected to experience growth opportunities due to rising incidences of stroke in the countries and rise development in the healthcare systems. The market is also expected to grow due to the rising awareness about the tumors and brain aneurysms in the countries of the region.
There has been an increase in the number of cases in SAM countries since the outbreak of COVID-19's second wave. According to the International Council of Nurses, due to high virus transmission, the number of mortalities among health professionals in Brazil is higher than in other nations. Currently, the countries in SAM are speedily increasing their clinical programs to fight against COVID-19. In this scenario, the pharmaceutical and biopharmaceutical companies are emphasizing on developing novel treatment therapies for the treatment of COVID-19, which is negatively impacting the market. Furthermore, due to the lockdowns imposed in several countries of SAM, the supply of blood and related products also diminished as people could not step outside their homes to donate. As the supply of blood diminished, it adversely affected plasma processing companies. Thus, the COVID-19 outbreak is likely to have a negative impact on market growth.
Market Overview and Dynamics
The plasma fractionation market in SAM is expected to grow from US$ 1,955.98 million in 2021 to US$ 2,663.87 million by 2028; it is estimated to grow at a CAGR of 4.5% from 2021 to 2028. The market players associated with metabolomics are actively exploring the possible innovative technologies to facilitate researchers and medical care as the plasma containing the essential components to treat a disease, such as antibodies. Various studies are being carried out on the possible applications of plasma for illnesses that are difficult to cure by employing traditional approaches. Moreover, rising awareness about the advantages of blood donation and applications of plasma among people is expected to open new scope for the market.
Key Market Segments
SAM plasma fractionation market is segmented into product, application, end user, and country. The SAM plasma fractionation market, based on product, has been segmented into immunoglobulin, albumin, coagulation factor concentrates, protease inhibitors, and others. The immunoglobulin segment is likely to hold the largest share of the market in 2021. The SAM plasma fractionation market, based on application is segmented into neurology, immunology, hematology, critical care, pulmonology, and others. In 2021, the Neurology segment is likely to hold the largest share of the market. The SAM plasma fractionation market, based on end user is segmented into hospitals and clinics, clinical research laboratories, academic institutes. In 2021, the hospitals and clinics segment is likely to hold the largest share of the market. Based on country, the SAM plasma fractionation market is segmented into Brazil, Argentina, and rest of SAM. Brazil held the largest market share in 2021.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the plasma fractionation market in SAM are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Bharat Serums and Vaccines Limited (BSV); Bio Products Laboratory Ltd.; Biotest AG; CSL Limited; Grifols, S.A.; Kedrion S.p.A; Octapharma AG; and SK Plasma.
Reasons to buy report
- To understand the SAM plasma fractionation market landscape and identify market segments that are most likely to guarantee a strong return.
- Stay ahead of the race by comprehending the ever-changing competitive landscape for SAM plasma fractionation market.
- Efficiently plan M&A and partnership deals in SAM plasma fractionation market by identifying market segments with the most promising probable sales.
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form SAM plasma fractionation market.
- Obtain market revenue forecast for market by various segments from 2021-2028 in SAM region.
SAM Plasma Fractionation Market Segmentation
SAM Plasma Fractionation Market - By Product
-
Immunoglobulin
- Intravenous Immunoglobulin (IVIG)
- Subcutaneous Immunoglobulin (SCIG)
- Albumin
- Coagulation Factor Concentrates
- Protease Inhibitors
- Other
SAM Plasma Fractionation Market - By Application
- Neurology
- Immunology
- Hematology
- Critical Care
- Pulmonology
- Others
SAM Plasma Fractionation Market - By End User
- Hospitals and Clinics
- Clinical Research Laboratories
- Academic Institutes
SAM Plasma Fractionation Market - By Country
- Brazil
- Argentina
- Rest of the SAM
SAM Plasma Fractionation Market - Company Profiles
- Bharat Serums and Vaccines Limited (BSV)
- Bio Products Laboratory Ltd.
- Biotest AG.
- CSL Limited
- Grifols, S.A.
- Kedrion S.p.A
- Octapharma AG
- SK Plasma
South America Plasma Fractionation Market Strategic Insights
South America Plasma Fractionation Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 1,955.98 Million |
| Market Size by 2028 | US$ 2,663.87 Million |
| CAGR (2021 - 2028) | 4.5% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product
|
|
Regions and Countries Covered
|
|
| South and Central America | Brazil, Argentina, Rest of South and Central America |
| Market leaders and key company profiles |
|
South America Plasma Fractionation Market Country and Regional Insights
